Bioactive Compound and Nanotechnology: A Novel Delivery Perspective for Diabetic Retinopathy

Author(s): Anima Debbarma, Probin Kr Roy*, Samia B. Barbhuiya, Jayita Das, Laldinchhana, Hauzel Lalhlenmawia

Journal Name: Current Bioactive Compounds

Volume 17 , Issue 8 , 2021


Article ID: e010621189484
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Diabetic retinopathy (DR) is one of the major complications of diabetes, and the consequences often lead to loss of vision. Currently, the treatments for DR are expensive, not easily available and the use of synthetic drugs leads to various toxic effects. Bioactive compound has been reported to be an alternative for the treatment of DR due to its ability to target multiple pathophysiological signaling pathways. However, bioactive compound suffers from some inherent physicochemical characteristics which restrict their use as therapeutic agents.

Objective: This review emphasizes an overview of the bioactive agents which are delivered as nano-formulation for safe and effective ocular delivery for the treatment of DR. Additional focus include site-specific ocular delivery with increased bioavailability to ensure highly efficacious treatment of DR.

Results: Utilization of various bioactive compounds such as polyphenols, flavonoids, tannins, etc., can counterbalance the damages that occur in the retinal tissues and thereby may ameliorate DR progression. Encapsulation of these bioactive compounds in a nanotechnology-based delivery system can improve bioavailability, reduce the toxic effect and achieve site-specific ocular delivery.

Conclusion: The pros and cons of bioactive compounds in treating DR and the use of nanotechnology to deliver bioactive compounds are discussed.

Keywords: Bioactive compounds, bioavailability of bioactive compound, diabetic retinopathy, nano-medicine, nanotechnology- based ocular delivery, targeted drug delivery.

[1]
Souto EB, Souto SB, Campos JR, et al. Nanoparticle delivery systems in the treatment of diabetes complications. Molecules 2019; 24(23): 4209.
[http://dx.doi.org/10.3390/molecules24234209] [PMID: 31756981]
[2]
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376(9735): 124-36.
[http://dx.doi.org/10.1016/S0140-6736(09)62124-3] [PMID: 20580421]
[3]
Ebneter A, Zinkernagel MS. Novelties in diabetic retinopathy. Endocr Dev 2016; 31: 84-96.
[http://dx.doi.org/10.1159/000439391] [PMID: 26824524]
[4]
Alghadyan AA. Diabetic retinopathy - An update. Saudi J Ophthalmol 2011; 25(2): 99-111.
[http://dx.doi.org/10.1016/j.sjopt.2011.01.009] [PMID: 23960911]
[5]
Kern TS. Kern. Interrelationships between the retinal neuroglia and vasculature in diabetes. Diabetes Metab J 2014; 38(3): 163-70.
[http://dx.doi.org/10.4093/dmj.2014.38.3.163] [PMID: 25003068]
[6]
Feenstra DJ, Yego EC, Mohr S. Modes of retinal cell death in diabetic retinopathy. J Clin Exp Ophthalmol 2013; 4(5): 298.
[PMID: 24672740]
[7]
Wei W, Amy CYL. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci 2018; 19(6): 1816.
[http://dx.doi.org/10.3390/ijms19061816] [PMID: 29899293]
[8]
Pipis A, Scholl S, Augustin AJ. Emerging drugs for diabetic retinopathy. Expert Opin Emerg Drugs 2011; 16(4): 669-81.
[http://dx.doi.org/10.1517/14728214.2011.640673] [PMID: 22112046]
[9]
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273.
[http://dx.doi.org/10.1155/2016/2156273] [PMID: 27761468]
[10]
Augustin AJ. Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system. Expert Opin Drug Deliv 2011; 8(2): 271-9.
[http://dx.doi.org/10.1517/17425247.2011.548802] [PMID: 21222552]
[11]
Anand KG, Gupta SK. Diabetic retinopathy: role of traditional medicinal plants in its management and their molecular mechanism. International Journal of Pharmaceutical Science Invention 2017; 6: 1-14.
[12]
Lei L, Yi J, Ravindran J, Yanli H. Current advances in pharmacotherapy and technology for diabetic retinopathy: a systematic review. J Ophthalmol 2018.
[13]
Ganesan P, Arulselvan P, Choi DK. Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus - current status. Int J Nanomedicine 2017; 12: 1097-111.
[http://dx.doi.org/10.2147/IJN.S124601] [PMID: 28223801]
[14]
Tsutomu Y, Yasuhiko T, Hideya K, Yuichiro O. Ocular drug delivery for bioactive proteins. Expert Rev Ophthalmol 2014; 6(6): 657-67.
[15]
Aldebasi YH, Aly SM, Rahmani AH. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int J Physiol Pathophysiol Pharmacol 2013; 5(4): 194-202.
[PMID: 24379904]
[16]
Satyaprakash B, Pir MI, Zaved A, Swati T, Siddhartha KM. Preventive roles of bioactive natural compounds in oxidative and nitrosative stress mediated pathophysiology of diabetes mellitus. asian j pharm clin res 2019; 12: 34-43.
[17]
Stanetic D, Buchbauer G. Biological activity of some volatile diterpenoids. Curr Bioact Compd 2015; 11: 38-48.
[http://dx.doi.org/10.2174/157340721101150804150419]
[18]
Abhishek S, Aheli S, Suresh CS, Steven LF, Zhang YD. Automated detection of diabetic retinopathy using convolutional neural networks on a small dataset. Pattern Recognit Lett 2020; 135: 293-8.
[http://dx.doi.org/10.1016/j.patrec.2020.04.026]
[19]
Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2017; 2(14): e93751.
[http://dx.doi.org/10.1172/jci.insight.93751] [PMID: 28724805]
[20]
Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs 2010; 70(16): 2171-200.
[http://dx.doi.org/10.2165/11538130-000000000-00000] [PMID: 20964459]
[21]
Aliouche L, Mosset P, León F, et al. Characterization of Chemical Compounds and Antioxidant Activity of Centaurea solstitialis sp. schouwii (DC.) Q. et S.(Asteraceae). Curr Bioact Compd 2020; 16(5): 618-26.
[http://dx.doi.org/10.2174/1573407215666190213125259]
[22]
Laldinchhana, Dutta RS, Thanzami K, Lalhlenmawia H, Pachuau L. Evaluation of the Food and Nutrition Value of RubusalceifoliusPoir. Fruits of Mizoram, India. Curr Nutr Food Sci 2020; 16(4): 554-62.
[http://dx.doi.org/10.2174/1573401315666190502162837]
[23]
Golkar P, Fotoohi A, Frezza C. Preliminary Phytochemical Screening, Evaluation of the Phenolic Compositions and Antioxidant Activities of Four Iranian Alyssum Species. Curr Bioact Compd 2020; 16(5): 581-7.
[http://dx.doi.org/10.2174/1573407215666190215152137]
[24]
Das A, Shakya A, Ghosh SK, Singh UP, Bhat HR. A review of phytochemical and pharmacological studies of inula species. Curr Bioact Compd 2020; 16(5): 557-67.
[http://dx.doi.org/10.2174/1573407215666190207093538]
[25]
Parveen A, Kim JH, Oh BG, Subedi L, Khan Z, Kim SY. Phytochemicals: target-based therapeutic strategies for diabetic retinopathy. Molecules 2018; 23(7): 1519.
[http://dx.doi.org/10.3390/molecules23071519] [PMID: 29937497]
[26]
Kaštelan S, Tomić M, Gverović Antunica A, Salopek Rabatić J, Ljubić S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm 2013; 2013: 213130.
[http://dx.doi.org/10.1155/2013/213130] [PMID: 24288441]
[27]
Da Silva SB, Costa JP, Pintado ME, Ferreira DC, Sarmento B. Antioxidants in the prevention and treatment of diabetic retinopathy a review. J Diabetes Metab 2010; 1: 111.
[http://dx.doi.org/10.4172/2155-6156.1000111]
[28]
Eskandani M, Bahadori MB, Zengin G, Dinparast L, Bahadori S. Novel natural agents from Lamiaceae family: an evaluation on toxicity and enzyme inhibitory potential linked to Diabetes Mellitus. Curr Bioact Compd 2016; 12: 34-8.
[http://dx.doi.org/10.2174/1573407212666151231183118]
[29]
Santini A, Novellino E. Nutraceuticals: beyond the diet before the drugs. Curr Bioact Compd 2014; 10: 1-12.
[http://dx.doi.org/10.2174/157340721001140724145924]
[30]
Rajalakshmi S, Vyawahare N, Pawar A, Mahaparale P, Chellampillai B. Current development in novel drug delivery systems of bioactive molecule plumbagin. Artificial cells, nanomedicine, and biotechnology 2018; 46(1): 209-18.
[http://dx.doi.org/10.1080/21691401.2017.1417865]
[31]
Vasant More S, Kim IS, Choi DK. Recent update on the role of chinese material medica and formulations in diabetic retinopathy. Molecules 2017; 22(1): 76.
[http://dx.doi.org/10.3390/molecules22010076] [PMID: 28054988]
[32]
Bilal M, Iqbal MS, Shah SB, Rasheed T, Iqbal HMN. Diabetic complications and insight into antidiabetic potentialities of ethno- medicinal plants: a review. Recent Pat Inflamm Allergy Drug Discov 2018; 12(1): 7-23.
[http://dx.doi.org/10.2174/1872213X12666180221161410] [PMID: 29473531]
[33]
Behl T, Kotwani A. Chinese herbal drugs for the treatment of diabetic retinopathy. J Pharm Pharmacol 2017; 69(3): 223-35.
[http://dx.doi.org/10.1111/jphp.12683] [PMID: 28124440]
[34]
Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27(10): 2540-53.
[http://dx.doi.org/10.2337/diacare.27.10.2540] [PMID: 15451934]
[35]
Switi BG, Krishna MG, Rani MS. Phytochemicals for diabetes management. Pharmaceutical Crops 2014; 5(1): 11-28.
[36]
Zhang HW, Zhang H, Grant SJ, Wan X, Li G. Single herbal medicine for diabetic retinopathy. Cochrane Database Syst Rev 2018; 12(12): CD007939.
[PMID: 30566763]
[37]
Da Silva SB, Borges S, Ramos O, Pintado M, Ferreira D, Sarmento B. Treating retinopathies–nanotechnology as a tool in protecting antioxidants agents.Systems Biology of Free Radicals and Antioxidants. 2014; pp. 3539-55.
[http://dx.doi.org/10.1007/978-3-642-30018-9_158]
[38]
Skopinski P, Szaflik J, Duda-Król B, et al. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Int J Mol Med 2004; 14(4): 707-11.
[http://dx.doi.org/10.3892/ijmm.14.4.707] [PMID: 15375605]
[39]
Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008; 9(4): 315-27.
[http://dx.doi.org/10.1007/s11154-008-9090-4] [PMID: 18654858]
[40]
Ola MS, Al-Dosari D, Alhomida AS. Role of oxidative stress in diabetic retinopathy and the beneficial effects of flavonoids. Curr Pharm Des 2018; 24(19): 2180-7.
[http://dx.doi.org/10.2174/1381612824666180515151043] [PMID: 29766782]
[41]
Song MK, Roufogalis BD, Huang TH. Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol 2012; 165(1): 4-19.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01411.x] [PMID: 21480863]
[42]
Ojha S, Balaji V, Sadek B, Rajesh M. Beneficial effects of phytochemicals in diabetic retinopathy: experimental and clinical evidence. Eur Rev Med Pharmacol Sci 2017; 21(11): 2769-83.
[PMID: 28678306]
[43]
Ali Hussain HE. Reversal of diabetic retinopathy in streptozotocin induced diabetic rats using traditional Indian anti-diabetic plant,Azadirachta indica (L.). Indian J Clin Biochem 2002; 17(2): 115-23.
[http://dx.doi.org/10.1007/BF02867983] [PMID: 23105362]
[44]
Garcia-Medina JJ, Vellosillo DRM, Moreno ZV, Medina GM, Pinazo-Duran MD, Pinazo GR. Antioxidant supplements and diabetic retinopathy. In Diabetes. Oxidative Stress and Dietary Antioxidants 2014; 22: 213-22.
[http://dx.doi.org/10.1016/B978-0-12-405885-9.00022-X]
[45]
Putta S, Yarla NS, Kumar K E, et al. Preventive and therapeutic potentials of anthocyanins in diabetes and associated complications. Curr Med Chem 2018; 25(39): 5347-71.
[http://dx.doi.org/10.2174/0929867325666171206101945] [PMID: 29210634]
[46]
Rossino MG, Casini G. Nutraceuticals for the treatment of diabetic retinopathy. Nutrients 2019; 11(4): 771.
[http://dx.doi.org/10.3390/nu11040771] [PMID: 30987058]
[47]
Lu LC, Zhou W, Li ZH, et al. Effects of arctiin on streptozotocin-induced diabetic retinopathy in Sprague-Dawley rats. Planta Med 2012; 78(12): 1317-23.
[http://dx.doi.org/10.1055/s-0032-1314998] [PMID: 22753037]
[48]
Tzeng TF, Liou SS, Tzeng YC, Liu IM. Zerumbone, a phytochemical of subtropical ginger, protects against hyperglycemia-induced retinal damage in experimental diabetic rats. Nutrients 2016; 8(8): 449.
[http://dx.doi.org/10.3390/nu8080449] [PMID: 27463726]
[49]
Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R. Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev 2015; 21: 1-15.
[http://dx.doi.org/10.1016/j.arr.2015.01.002] [PMID: 25625901]
[50]
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4(6): 807-18.
[http://dx.doi.org/10.1021/mp700113r] [PMID: 17999464]
[51]
Guidetti B, Azéma J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr Drug Deliv 2008; 5(1): 7-19.
[http://dx.doi.org/10.2174/156720108783331050] [PMID: 18220546]
[52]
Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv 2014; 5(12): 1297-315.
[http://dx.doi.org/10.4155/tde.14.75] [PMID: 25531930]
[53]
Bhattacharjee A, Das PJ, Adhikari P, et al. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery. Eur J Ophthalmol 2019; 29(1): 113-26.
[http://dx.doi.org/10.1177/1120672118769776] [PMID: 29756507]
[54]
Firoz MV, Vishal GN, Sandeep K. The current trends and treatments in diabetic retinopathy. Asian Journal of Pharmaceutical and Clinical Research 2019; 12(7): 27-33.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i7.33774]
[55]
Selvaraj K, Gowthamarajan K, Karri VV, Barauah UK, Ravisankar V, Jojo GM. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. J Drug Target 2017; 25(5): 386-405.
[http://dx.doi.org/10.1080/1061186X.2017.1280809] [PMID: 28122462]
[56]
Zorzi GK, Carvalho EL, Poser VGL, Teixeira HF. On the use of nanotechnology-based strategies for association of complex matrices from plant extracts. Rev Bras Farmacogn 2015; 25(4): 426-36.
[http://dx.doi.org/10.1016/j.bjp.2015.07.015]
[57]
Yadav K, Chauhan NS, Saraf S, Singh D, Singh MR. Challenges and need of delivery carriers for bioactives and biological agents: an introduction.In Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. 2020; pp. 1-36.
[58]
Souto EB, Dias-Ferreira J, López-Machado A, et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics 2019; 11(9): 460.
[http://dx.doi.org/10.3390/pharmaceutics11090460] [PMID: 31500106]
[59]
Cavet ME, Harrington KL, Vollmer TR, Ward KW, Zhang JZ. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol Vis 2011; 17: 533-42.
[PMID: 21364905]
[60]
Fangueiro JF, Andreani T, Fernandes L, et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B Biointerfaces 2014; 123: 452-60.
[http://dx.doi.org/10.1016/j.colsurfb.2014.09.042] [PMID: 25303852]
[61]
Huang HY, Wang MC, Chen ZY, et al. Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief. Int J Nanomedicine 2018; 13: 7251-73.
[http://dx.doi.org/10.2147/IJN.S173198] [PMID: 30510416]
[62]
Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine 2014; 9: 1-15.
[PMID: 24363556]
[63]
Sutradhar KB, Amin ML. Nanoemulsions: increasing possibilities in drug delivery. Eur J Nanomed 2013; 5(2): 97-110.
[http://dx.doi.org/10.1515/ejnm-2013-0001]
[64]
Moghimipour E, Salimi A, Yousefvand T. Preparation and evaluation of celecoxib nanoemulsion for ocular drug delivery. Asian Journal of Pharmaceutics 2017; 11(3): S543.
[65]
Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. J Drug Deliv Sci Technol 2019; 51: 224-33.
[http://dx.doi.org/10.1016/j.jddst.2019.03.006]
[66]
Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Delivery 2012.
[http://dx.doi.org/10.1155/2012/604204]
[67]
Shah J, Nair AB, Jacob S, et al. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics 2019; 11(5): 230.
[http://dx.doi.org/10.3390/pharmaceutics11050230] [PMID: 31083593]
[68]
Hu BJ, Hu YN, Lin S, Ma WJ, Li XR. Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy. Int J Ophthalmol 2011; 4(3): 303-6.
[PMID: 22553667]
[69]
Abdel-Aal SM, Akhtar H, Zaheer K, Ali R. Dietary sources of lutein and zeaxanthin carotenoids and their role in eye health. Nutrients 2013; 5(4): 1169-85.
[http://dx.doi.org/10.3390/nu5041169] [PMID: 23571649]
[70]
Neelam K, Goenadi CJ, Lun K, Yip CC, Au Eong KG. Putative protective role of lutein and zeaxanthin in diabetic retinopathy. Br J Ophthalmol 2017; 101(5): 551-8.
[http://dx.doi.org/10.1136/bjophthalmol-2016-309814] [PMID: 28232380]
[71]
Lim C, Kim DW, Sim T, et al. Preparation and characterization of a lutein loading nanoemulsion system for ophthalmic eye drops. J Drug Deliv Sci Technol 2016; 36: 168-74.
[http://dx.doi.org/10.1016/j.jddst.2016.10.009]
[72]
Kumara SK, Phanindra A, Nagaraj A, Anil GK, Shiva KR. Liposomes as ocular drug delivery platforms: a review. Saudi J Med Pharm Sci 2017; 3(7B): 808-12.
[73]
Ajazuddin SS, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia 2010; 81(7): 680-9.
[http://dx.doi.org/10.1016/j.fitote.2010.05.001] [PMID: 20471457]
[74]
Lai S, Wei Y, Wu Q, et al. Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology 2019; 17(1): 64.
[http://dx.doi.org/10.1186/s12951-019-0498-7] [PMID: 31084611]
[75]
Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine 2013; 8: 495-503.
[http://dx.doi.org/10.2147/IJN.S30725] [PMID: 23439842]
[76]
Chen MW, Zhou YF, Huang JJ, Zhu P, Peng XS, Wang YT. Liposome-based delivery systems in plant polysaccharides. J Nanomater 2012.
[http://dx.doi.org/10.1155/2012/682545]
[77]
John M, Gacche RN. Nano-formulations for ophthalmic treatments. Arch Pharm Pharma Sci 2017; 1: 028-35.
[78]
Xiao JR, Do CW, To CH. Potential therapeutic effects of baicalein, baicalin, and wogonin in ocular disorders. J Ocul Pharmacol Ther 2014; 30(8): 605-14.
[http://dx.doi.org/10.1089/jop.2014.0074] [PMID: 25280175]
[79]
Dai C, Jiang S, Chu C, Xin M, Song X, Zhao B. Baicalin protects human retinal pigment epithelial cell lines against high glucose-induced cell injury by up-regulation of microRNA-145. Exp Mol Pathol 2019; 106: 123-30.
[http://dx.doi.org/10.1016/j.yexmp.2019.01.002] [PMID: 30625293]
[80]
Liang R, Han RM, Fu LM, Ai XC, Zhang JP, Skibsted LH. Baicalin in radical scavenging and its synergistic effect with β-carotene in antilipoxidation. J Agric Food Chem 2009; 57(15): 7118-24.
[http://dx.doi.org/10.1021/jf9013263] [PMID: 19722585]
[81]
Jung SH, Kang KD, Ji D, et al. The flavonoid baicalin counteracts ischemic and oxidative insults to retinal cells and lipid peroxidation to brain membranes. Neurochem Int 2008; 53(6-8): 325-37.
[http://dx.doi.org/10.1016/j.neuint.2008.09.004] [PMID: 18835309]
[82]
Wu H, Liu Z, Peng J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm 2011; 410(1-2): 31-40.
[http://dx.doi.org/10.1016/j.ijpharm.2011.03.007] [PMID: 21397671]
[83]
Ashraf O, Nasr M, Nebsen M, Said AMA, Sammour O. In vitro stabilization and in vivo improvement of ocular pharmacokinetics of the multi-therapeutic agent baicalin: Delineating the most suitable vesicular systems. Int J Pharm 2018; 539(1-2): 83-94.
[http://dx.doi.org/10.1016/j.ijpharm.2018.01.041] [PMID: 29374518]
[84]
Yang Y, Guo Y, Sun R, Wang X. Self-assembly and β-carotene loading capacity of hydroxyethyl cellulose-graft-linoleic acid nanomicelles. Carbohydr Polym 2016; 145: 56-63.
[http://dx.doi.org/10.1016/j.carbpol.2016.03.012] [PMID: 27106151]
[85]
Hu Y, Bao C, Li D, et al. The construction of enzymolyzed α-lactalbumin based micellar nanoassemblies for encapsulating various kinds of hydrophobic bioactive compounds. Food Funct 2019; 10(12): 8263-72.
[http://dx.doi.org/10.1039/C9FO02035G] [PMID: 31720654]
[86]
Borowy-Borowski H, Sodja C, Docherty J, Walker PR, Sikorska M. Unique technology for solubilization and delivery of highly lipophilic bioactive molecules. J Drug Target 2004; 12(7): 415-24.
[http://dx.doi.org/10.1080/10611860412331285233] [PMID: 15621666]
[87]
Martin RC, Locatelli E, Li Y, et al. Gold nanorods and curcumin-loaded nanomicelles for efficient in vivo photothermal therapy of Barrett’s esophagus. Nanomedicine (Lond) 2015; 10(11): 1723-33.
[http://dx.doi.org/10.2217/nnm.15.25] [PMID: 25706349]
[88]
Vadlapudi AD, Mitra AK. Nanomicelles: an emerging platform for drug delivery to the eye. Ther Deliv 2013; 4(1): 1-3.
[http://dx.doi.org/10.4155/tde.12.122] [PMID: 23323774]
[89]
Li M, Xin M, Guo C, Lin G, Wu X. New nanomicelle curcumin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment. Drug Dev Ind Pharm 2017; 43(11): 1846-57.
[http://dx.doi.org/10.1080/03639045.2017.1349787] [PMID: 28665151]
[90]
Guo C, Li M, Qi X, et al. Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice. Sci Rep 2016; 6(1): 29753.
[http://dx.doi.org/10.1038/srep29753] [PMID: 27405815]
[91]
Alshamrani M, Sikder S, Coulibaly F, Mandal A, Pal D, Mitra AK. Self-assembling topical nanomicellar formulation to improve curcumin absorption across ocular tissues. AAPS PharmSciTech 2019; 20(7): 254.
[http://dx.doi.org/10.1208/s12249-019-1404-1] [PMID: 31317354]
[92]
López-Malo D, Villarón-Casares CA, Alarcón-Jiménez J, et al. Curcumin as a therapeutic option in retinal diseases. Antioxidants 2020; 9(1): 48.
[http://dx.doi.org/10.3390/antiox9010048] [PMID: 31935797]
[93]
Nath J, Kalita B, Das G. Curcumin and its nanoformulations: a comprehensive overview for the management of diabetes complications. Int J Curr Pharm Sci 2019; 11(4): 18-21.
[http://dx.doi.org/10.22159/ijcpr.2019v11i4.34932]
[94]
Fangueiro JF, Silva AM, Garcia ML, Souto EB. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm 2015; 95(B): 307-22.
[http://dx.doi.org/10.1016/j.ejpb.2014.12.023]
[95]
Huang M, Liang C, Tan C, et al. Liposome co-encapsulation as a strategy for the delivery of curcumin and resveratrol. Food Funct 2019; 10(10): 6447-58.
[http://dx.doi.org/10.1039/C9FO01338E] [PMID: 31524893]
[96]
Dong Y, Wan G, Yan P, Qian C, Li F, Peng G. Fabrication of resveratrol coated gold nanoparticles and investigation of their effect on diabetic retinopathy in streptozotocin induced diabetic rats. J Photochem Photobiol B 2019; 195: 51-7.
[http://dx.doi.org/10.1016/j.jphotobiol.2019.04.012] [PMID: 31082734]
[97]
Dewanjee S, Chakraborty P, Mukherjee B, De Feo V. Plant-based antidiabetic nanoformulations: the emerging paradigm for effective therapy. Int J Mol Sci 2020; 21(6): 2217.
[http://dx.doi.org/10.3390/ijms21062217] [PMID: 32210082]
[98]
Wang J, Tan J, Luo J, et al. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. J Nanobiotechnology 2017; 15(1): 18.
[http://dx.doi.org/10.1186/s12951-017-0251-z] [PMID: 28249594]
[99]
Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid Med Cell Longev 2014; 2014: 752387.
[http://dx.doi.org/10.1155/2014/752387] [PMID: 25180070]
[100]
Jimnéz-Fernández E, Zuasti E, Ruyra A, Roher N, Infante C, Fernández-Díaz C. Nanoparticles as a novel delivery system for vitamin C administration in aquaculture. Commun Agric Appl Biol Sci 2013; 78(4): 202-3.
[PMID: 25141667]
[101]
Alishahi A, Mirvaghefi A, Tehrani MR, et al. Shelf life and delivery enhancement of vitamin C using chitosan nanoparticles. Food Chem 2011; 126(3): 935-40.
[http://dx.doi.org/10.1016/j.foodchem.2010.11.086]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 8
Year: 2021
Published on: 24 December, 2020
Article ID: e010621189484
Pages: 13
DOI: 10.2174/1573407216999201224145751
Price: $65

Article Metrics

PDF: 106
HTML: 1